SCHEMBL5863916

SCHEMBL5863916

Cc1cccc(CN2CCc3ccc(N4CCN(CCCCC5(C(=O)NCC(F)(F)F)c6ccccc6Sc6ccccc65)CC4)cc3C2=O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
DRD3 P35462 10/20 0.40
DRD1 P21728 4/20 0.40
DRD2 P14416 5/20 0.39
MTTP P55157 2/20 0.38
KCNH2 Q12809 2/20 0.38
CHRM2 P08172 1/20 0.38
ADRA2A P08913 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
CHRM1 P11229 1/20 0.38
TBXA2R P21731 1/20 0.38
PTGS1 P23219 1/20 0.38
SLC6A2 P23975 1/20 0.38
ADRA1A P35348 1/20 0.38
OPRM1 P35372 1/20 0.38
SLC6A3 Q01959 1/20 0.38
MTR Q99707 1/20 0.38
TP53 P04637 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5864071 0.98 LMNA (0.43) LMNADRD3DRD1DRD2MTTP
SCHEMBL5864413 0.94 LMNA (0.43) LMNADRD3DRD1DRD2MTTP
SCHEMBL5863806 0.93 DRD3 (0.44) LMNADRD3DRD1DRD2MTTP
SCHEMBL5863599 0.93 DRD3 (0.41) DRD3DRD1DRD2MTTPKCNH2
SCHEMBL5864105 0.93 DRD3 (0.40) LMNADRD3DRD1DRD2MTTP
SCHEMBL5863391 0.92 DRD1 (0.40) LMNADRD3DRD1DRD2MTTP
SCHEMBL5863803 0.92 LMNA (0.43) LMNADRD3DRD1DRD2MTTP
SCHEMBL5863749 0.92 LMNA (0.42) LMNADRD3DRD1DRD2KCNH2
SCHEMBL5863978 0.92 DRD3 (0.49) DRD3DRD1DRD2HTR1AHTR2A
SCHEMBL5864325 0.92 LMNA (0.43) LMNADRD3DRD1DRD2MTTP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030120-B2 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-18 US disclosed
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same OHKURA NAOTO (JP) 2004-11-11 US disclosed
US-6777414-B1 INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA MEIJI SEIKA KAISHA, LTD. (JP) 2004-08-17 US disclosed
EP-1180514-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2002-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same APOB, NCEH1, LIPC LMNA 508/4885DRD3 862/4885DRD1 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.